12 results
8-K
EX-99.1
GOSS
Gossamer Bio Inc
6 May 24
Entry into a Material Definitive Agreement
7:31am
this therapy to patients world-wide,” said Giuseppe Accogli, Group CEO of Chiesi. “Gossamer shares Chiesi’s commitment to using innovation to promote the health
10-K
2018 FY
GOSS
Gossamer Bio Inc
22 Mar 19
Annual report
4:45pm
innovation to develop, strengthen and maintain our proprietary position. We also plan to rely on data exclusivity, market exclusivity and patent term … Safety and Innovation Act established a category of drugs referred to as “breakthrough therapies” that may be eligible to receive breakthrough therapy
S-1/A
9yhqwacup10kn
23 Jan 19
IPO registration (amended)
4:39pm
424B4
55iod z5a
8 Feb 19
Prospectus supplement with pricing info
4:40pm
S-1
lxuwkyuatc0qch4v3
21 Dec 18
IPO registration
4:39pm
DRS/A
e18z6qoew av
29 Nov 18
Draft registration statement (amended)
12:00am
DRS
6cacvr0hmvkb16bmz
11 Oct 18
Draft registration statement
12:00am
- Prev
- 1
- Next